What is a "Second Request" from the DOJ, and what does it mean for the CVS Health-Aetna merger?

A "Second Request" is an official request for detailed information and documents by the U.S. Department of Justice (DOJ) during its antitrust review of a merger. It signifies that the DOJ requires more time and scrutiny to assess potential competitive impacts. This request extends the waiting period under the Hart-Scott-Rodino (HSR) Act, meaning the merger cannot close until the DOJ completes its review or the waiting period is otherwise terminated.

Will the "Second Request" delay the closing of the Aetna acquisition?

While a "Second Request" does extend the regulatory waiting period, CVS Health reiterated its expectation that the transaction will still be completed in the second half of 2018. The exact impact on the closing date will depend on how quickly CVS Health and Aetna can substantially comply with the DOJ's request and the DOJ's subsequent review timeline. Investors should be prepared for potential variability but note management's current outlook.

What are the next key steps for the merger to be completed?

The key upcoming steps for the merger include obtaining necessary regulatory approvals (which is currently undergoing enhanced scrutiny with the DOJ's "Second Request"), and securing approval from both CVS Health stockholders and Aetna shareholders. The company has scheduled stockholder meetings for March 20, 2018, to vote on the transaction. The satisfaction of other closing conditions specified in the merger agreement is also required.

Where can I find more detailed information about the merger and related filings?

Investors and security holders are urged to read the joint proxy statement/prospectus and other documents filed with the SEC by CVS Health and Aetna. These documents can be found on the SEC's website (sec.gov), CVS Health's investor relations website, and Aetna's investor relations website. Specific contact information for investor relations is provided in the filing for obtaining copies of these documents.

CVS 8-K SEC Disclosure

Summary

CVS Health Corporation filed this 8-K on February 1, 2018, to announce that it and Aetna Inc. received a "Second Request" from the U.S. Department of Justice (DOJ) regarding their proposed merger. This request extends the waiting period under the Hart-Scott-Rodino (HSR) Act, indicating a more in-depth antitrust review is underway. While this adds a procedural step, CVS Health reiterated its expectation that the transaction will still close in the second half of 2018. The company also noted that both companies have scheduled stockholder meetings for March 20, 2018, to seek necessary approvals for the merger. Investors should monitor regulatory developments and the outcomes of the stockholder votes closely as key determinants of the deal's completion timeline and terms. This filing serves primarily as an update on the regulatory process for the significant Aetna acquisition. The "Second Request" implies the DOJ requires more time and information to assess potential antitrust concerns. Despite this, CVS Health maintains its previously stated closing timeline, suggesting management's confidence in navigating the regulatory hurdles. The upcoming stockholder meetings are critical junctures for the deal's progression. Investors should pay close attention to any further communications regarding regulatory feedback and the voting outcomes.

Key Highlights

1CVS Health and Aetna received a "Second Request" for additional information from the DOJ concerning the proposed merger, extending the HSR Act waiting period.
2The "Second Request" signifies a more thorough antitrust review by the DOJ.
3CVS Health continues to expect the transaction to be completed in the second half of 2018, despite the extended review timeline.
4Both CVS Health and Aetna have scheduled stockholder meetings for March 20, 2018, to vote on the merger agreement.
5The transaction remains subject to various closing conditions, including regulatory approvals and stockholder votes.
6The filing includes customary "no offer or solicitation" and "additional information" disclaimers regarding the merger and related filings.

CVS HEALTH Corp 8-K Report, Corporate Update (Feb 1, 2018)

Summary

Key Highlights

Frequently Asked Questions